Table V.

Protective responses in VgB-immune B cell-deficient micea

MiceImmunizationChallenge DosebVaginal Virus TiterNo. Surviving Challengec
Day 2Day 5
μMT−/−VgBLow dose3.1 ± 1.6 (6/6)d0.6 ± 1.6 (1/6)6/6
BALB/cVgB2.2 ± 1.0 (5/6)0.0 (0/6)6/6
BALB/cVV5.4 ± 0.4 (7/7)3.5 ± 0.4 (7/7)0/7
μMT−/−VgBHigh dose5.1 ± 0.1 (4/4)1.2 ± 1.1 (3/4)4/4
BALB/cVgB4.7 ± 0.6 (4/4)1.1 ± 1.2 (3/4)4/4
BALB/cVV6.0 ± 0.6 (4/4)5.6 ± 0.6 (4/4)0/4
  • a Groups of 6 female μMT−/− or BALB/c mice were immunized i/nas with 1 × 107 pfu of VgB. Additionally, a group of BALB/c mice was given VV i/nas and used as controls. Fifteen days after immunization, all mice were injected with 2 mg/mouse DP. Five days later, the mice were challenged intravaginally with 1 × 105 or 1 × 107 pfu of HSV-1 McKrae (200 LD50). Vaginal washings were collected at days 2 and 5 after challenge, and the titers were determined by plaque assay. BALB/c and μMT−/− mice were bled at day 30 after immunization, and the serum anti-HSV IgG titers were determined by ELISA. On average, immune BALB/c mice had titers of 20,305 ng/ml, whereas immune μMT−/− mice had titers of <355 ng/ml.

  • b Low dose, 105 pfu; high dose, 2 × 107 pfu.

  • c Number of surviving mice/number of mice used.

  • d Number of mice positive for virus/number of mice tested.